https://doctransparency.com/doctor/tx/houston/rocio-harbison-1881710499
Medicare Enrolled

Dr. Rocio Harbison, MD

Endocrinology · Houston, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
7400 FANNIN ST STE 855, Houston, TX 77054
7137969466
In practice since 2007 (19 years)
NPI: 1881710499 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Harbison from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Harbison? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Harbison

Dr. Rocio Harbison is an endocrinology in Houston, TX, with 19 years in practice. Based on federal Medicare data, Dr. Harbison performed 2,502 Medicare services across 658 unique beneficiaries.

Between the years covered by Open Payments, Dr. Harbison received a total of $1,001,927 from 59 pharmaceutical and/or device companies across 1605 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Harbison is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 18% volume in TX$ $1,001,927 industry payments

Medicare Practice Summary

Medicare Utilization ↗
2,502
Medicare services
Top 18% in TX for endocrinology
658
Unique beneficiaries
$37
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~132 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Denosumab injection (Prolia/Xgeva)1,500$18$40
Office visit, established patient (30-39 min)400$94$221
Hemoglobin A1c test (diabetes monitoring)144$9$50
Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report125$26$91
Blood glucose (sugar) level74$4$30
Office visit, established patient, complex (40-54 min)61$135$297
Lipid panel (cholesterol and triglycerides)52$13$50
Drug injection, under skin or into muscle30$11$53
New patient office visit (45-59 min)28$132$337
Complete ultrasound study of arm and leg arteries24$93$283
Testing of autonomic (sympathetic) nervous system function22$93$290
Testing of autonomic nervous system function and heart rate response to deep breathing21$66$176
New patient office visit, complex (60-74 min)21$161$424
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$1,001,927
Total received (2018-2024)
Avg $143,132/year across 7 years
Top 2% in TX for endocrinology
59
Companies
1,605
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$938,675 (93.7%)
Financial / Ownership
Ownership or investment interests, royalties, and licensing fees
$43,203 (4.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$11,253 (1.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,392 (0.5%)
Other
Charitable contributions, space rental, and other categories
$3,404 (0.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$150,702
2023
$118,726
2022
$200,131
2021
$116,987
2020
$138,510
2019
$125,741
2018
$151,129

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novo Nordisk Inc
$350,839
Lilly USA, LLC
$184,671
Corcept Therapeutics
$161,553
AstraZeneca Pharmaceuticals LP
$102,513
Medtronic, Inc.
$47,814
Medtronic MiniMed, Inc.
$43,267
Dexcom, Inc.
$32,666
Tandem Diabetes Care, Inc.
$28,552
SANOFI-AVENTIS U.S. LLC
$21,784
AbbVie Inc.
$9,246
Companion Medical, Inc.
$4,677
ABBVIE INC.
$2,731
DEXCOM, INC.
$2,393
IBSA Pharma Inc.
$2,057
AbbVie, Inc.
$2,022
ModernaTX, Inc.
$1,553
Janssen Pharmaceuticals, Inc
$598
Bigfoot Biomedical Inc
$360
Amgen Inc.
$359
Valeritas, Inc.
$232
Boehringer Ingelheim Pharmaceuticals, Inc.
$227
Insulet Corporation
$160
BETA BIONICS, INC.
$144
Xeris Pharmaceuticals, Inc.
$137
CeQur Corporation
$116
Abbott Laboratories
$109
Mannkind Corporation
$92
Shire North American Group Inc
$90
Amarin Pharma Inc.
$79
KVK-Tech, Inc.
$78
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$77
Astellas Pharma US Inc
$62
Senseonics, Incorporated
$60
Synergy Pharmaceuticals Inc
$42
Zealand Pharma US, Inc.
$40
Alexion Pharmaceuticals, Inc.
$39
Radius Health, Inc.
$36
Novartis Pharmaceuticals Corporation
$34
Intuity Medical Inc
$34
Kowa Pharmaceuticals America, Inc.
$30
Bayer HealthCare Pharmaceuticals Inc.
$29
VistaPharm, Inc.
$27
GRT US Holding, Inc.
$27
Amneal Pharmaceuticals LLC
$27
Merck Sharp & Dohme Corporation
$25
Esperion Therapeutics, Inc.
$20
Strongbridge US INC.
$19
RECORDATI_RARE_DISEASES_INC.
$19
Supernus Pharmaceuticals, Inc.
$18
VIVUS LLC
$17
TherapeuticsMD, Inc.
$16
LifeScan, Inc.
$16
Regeneron Healthcare Solutions, Inc.
$15
VIVUS, Inc.
$15
Eisai Inc.
$15
Vertical Pharmaceuticals, LLC
$14
Antares Pharma, Inc.
$14
AMAG Pharmaceuticals, Inc.
$12
Currax Pharmaceuticals LLC
$10
Top 3 companies account for 69.6% of total payments
Associated products mentioned in payments ›
AFREZZA · BYDUREON · CONTRAVE · CYCLOSET · CeQur Simplicity · DEXCOM CGM · DEXCOM G6 CGM SYSTEM · DEXCOM G6 TRANSMITTER · DEXCOM G7 GSS (161) · DIVIGEL · Dayvigo · Dexcom CGM · Dexcom G6 Transmitter · ENTRESTO · EVENITY · Eversense · FARXIGA · FREESTYLE LIBRE 3 · FreeStyle Libre · GVOKE HYPOPEN · GVOKE PFS · HUMULIN · IMVEXXY · INPEN SMART INSULIN DELIVERY SYSTEM · INTRAROSA · INVOKANA · InPen · JANUVIA · JARDIANCE · Kerendia · Korlym · LANTUS · LEQVIO · LICART · LINZESS · Levemir · Livalo · MACRILEN · MINIMED 770G · MINIMED 780G · MOUNJARO · Minimed 530G · Minimed 670G System · Myrbetriq · NATPARA · NATPARA (PARATHYROID HORMONE) · NEXLETOL · NO PRODUCT DISCUSSED · NOCDURNA · NovoLog · Omnipod · OneTouch · Ozempic · PRALUENT · Pogo Automatic Blood Glucose Monitoring System · Prolia · QSYMIA · Qsymia · Qutenza · RECORLEV · RYBELSUS · Repatha · Rybelsus · SIGNIFOR LAR · SOLIQUA · SOLIQUA 100/33 · STRENSIQ · SYNTHROID · Saxenda · Synthroid · TEPEZZA · TOUJEO · TRADJENTA · TRULANCE · TRULICITY · Thyquidity · Tirosint · Tresiba · Trulance · Tymlos · UBRELVY · UNITHROID · UNITY DIABETES MANAGEMENT SYSTEM · V-GO · V-GO DISPOSABLE INSULIN DELIVERY · VIBERZI · Vascepa · Veozah · Victoza · Wegovy · XIFAXAN · XYOSTED · Xultophy 100/3.6 · iLet Bionic Pancreas · t-slim insulin pump · t:slim X2 Insulin Pump with Control-IQ · t:slim X2 insulin pump
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in endocrinology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for endocrinology in TX.

Equivalent to $40,045 per 100 Medicare services performed
Looking for a endocrinology in Houston?
Compare endocrinologys in the Houston area by procedure volume, costs, and industry payment transparency.
Browse endocrinologys nearby

Geographic Context

Endocrinologys within 10 mi
142
Per 100K population
3.0
County median income
$73,104
Nearest hospital
WOMANS HOSPITAL OF TEXAS,THE
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Harbison is a clinical cardiology specialist, with above-average Medicare volume (top 18% in TX), and high industry engagement (speaking/promotional, top 2%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Harbison experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Harbison performed 1,500 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Harbison receive payments from pharmaceutical companies?
Yes. Dr. Harbison received a total of $1,001,927 from 59 companies across 1,605 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Harbison's costs compare to other endocrinologys in Houston?
Dr. Harbison's average Medicare payment per service is $37. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Harbison) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →